| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | 24.0 | 11.2 |
| Profit before tax | -74.7 | -98.5 |
| Net income | -74.7 | -98.5 |
| EPS (diluted, $ a share) | $-0.74 | $-1.35 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
| Revenue, year on year | +113.6% |
|---|---|
| Operating margin | -313.3% |
10-Q filed with the SEC, NASDAQ: VSTM. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Verastem, Inc.: key numbers
- Share price
- $7.70Close, Nov 16
- Market cap
- $970M
- Shares outstanding
- 126.01MLatest SEC cover page
- Sector
- Life Sciences
- Industry
- Pharmaceutical PreparationsSIC 2834
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Verastem, Inc.
All →Verastem President and CEO Dan Paterson Sells $12.5K of Stock
Dan Paterson, President and CEO, sold 1,299 shares of Verastem, Inc. at $9.60 a share, worth $12.5K in total on Nov 3, 2026. Shares held after the trade: 651,413 (-0.2%).
- Value
- $12.5K
- Shares
- 1,299
- Price
- $9.60
- Role
- President and CEO
- Holding change
- -0.2%
- Trade date
- Nov 3, 2026
Verastem Investor Presentation
Verastem Oncology (VSTM) has published an updated corporate presentation for November 2026 detailing its pipeline of RAS/MAPK pathway-driven cancer therapies. The presentation highlights the commercialization strategy for AVMAPKI FAKZYNJA CO-PACK in recurrent low-grade serous ovarian cancer (LGSOC) and provides updates on its clinical trial programs, including RAMP 301 and collaborations with GenFleet Therapeutics.
Verastem Capital Raise of $235M
Verastem, Inc. entered into an underwriting agreement for a public offering of 30,937,500 shares of common stock and pre-funded warrants to purchase 312,503 shares. The common stock is priced at $8.00 per share, with the company expecting to receive net proceeds of approximately $234.7 million. The offering is expected to close on or about October 15, 2026.
- Value
- $235M
- Counterparty
- Jefferies LLC and Guggenheim Securities, LLC
Verastem Leadership Change
Verastem Oncology announced that Daniel W. Paterson will retire as President and CEO effective January 1, 2027, and will be succeeded by Michael P. Bailey. Mr. Paterson will remain on the Board of Directors and serve as an advisor, while Mr. Bailey, an existing director with over 30 years of industry experience, will lead the company's next phase of commercial growth.
Verastem President and CEO Dan Paterson Sells $353K of Stock
Dan Paterson, President and CEO, sold 44,121 shares of Verastem, Inc. at $8.00 a share, worth $353K in total on Oct 1, 2026. Shares held after the trade: 652,712 (-6.3%).
- Value
- $353K
- Shares
- 44,121
- Price
- $8.00
- Role
- President and CEO
- Holding change
- -6.3%
- Trade date
- Oct 1, 2026
Verastem CFO Daniel Calkins Sells $20.5K of Stock
Daniel Calkins, CFO, sold 2,566 shares of Verastem, Inc. at $8.00 a share, worth $20.5K in total on Oct 1, 2026. Shares held after the trade: 123,781 (-2.0%).
- Value
- $20.5K
- Shares
- 2,566
- Price
- $8.00
- Role
- CFO
- Holding change
- -2.0%
- Trade date
- Oct 1, 2026